Product nameAnti-CD45.1 antibody [A20] (PE/Cy5®)
See all CD45.1 primary antibodies
DescriptionMouse monoclonal [A20] to CD45.1 (PE/Cy5®)
ConjugationPE/Cy5®. Ex: 496nm, Em: 670nm
SpecificityThe monoclonal antibody A20 recognizes all mouse leukocytes expressing the CD 45.1 allotype.
Tested applicationsSuitable for: Flow Cyt, ICC/IF, IP, Functional Studiesmore details
Species reactivityReacts with: Mouse
The details of the immunogen for this antibody are not available.
General notesThis product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: PBS, 0.2% Gelatin, 16% Sucrose
Concentration information loading...
Light chain typekappa
- Anti-CD45.1 antibody [A20] (PerCP/Cy5.5®) (ab210237)
- Anti-CD45.1 antibody [A20] (FITC) (ab24917)
- Anti-CD45.1 antibody [A20] (Cy5 ®) (ab24982)
- Anti-CD45.1 antibody [A20] (Biotin) (ab25011)
- Anti-CD45.1 antibody [A20] (Phycoerythrin) (ab25012)
- Anti-CD45.1 antibody [A20] (ab25078)
- Anti-CD45.1 antibody [A20] (Allophycocyanin) (ab25348)
- Anti-CD45.1 antibody [A20] (Allophycocyanin/Cy7 ®) (ab46823)
Our Abpromise guarantee covers the use of ab25349 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use 0.2µg for 106 cells.|
|ICC/IF||Use at an assay dependent dilution.|
|IP||Use at an assay dependent dilution.|
|Functional Studies||Use at an assay dependent dilution. As a marker of the origin of donor and host cells.|
RelevanceCD45 is an essential regulator of leukocyte activation and development, and is now known to be a protein tyrosine phosphatase, e.g. CD45 is able to dephosphorylate the Src family of protein kinases. This activity is now known to be required for signal transduction induced by T and B cell antigen receptor engagement, cytokine signaling and Fc receptor stimulation. The functional state of CD45 also has a pronounced effect on lymphocyte development. CD45 exists in multiple forms, such as the restricted variants and as allelic forms CD45.1/Ly5.1 and CD45.2/Ly5.2. The former arises as a result of alternative splicing of different exons. The specificity of antibodies to CD45.1 and CD45.2 has been exploited in studies in which resolution of donor and recipient cells is essential, such as in gene therapy or bone marrow transplantation.
Cellular localizationType I membrane protein.
- B220 antibody
- CD45 antibody
- CD45 antigen antibody
This product has been referenced in:
- Mardiney M & Malech HL Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood 87:4049-56 (1996). Read more (PubMed: 8639760) »
- Vallera DA et al. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 57:249-56 (1994). Read more (PubMed: 7906058) »